<?xml version='1.0' encoding='utf-8'?>
<document id="21731754"><sentence text="Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study." /><sentence text="Bleeding is the most common and worrisome adverse effect of warfarin therapy" /><sentence text=" One of the factors that might increase bleeding risk is initiation of interacting drugs that potentiate warfarin" /><sentence text=" We sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users" /><sentence text="" /><sentence text="Medicaid claims data (1999-2005) were used to perform an observational case-control study nested within person-time exposed to warfarin in those ≥18 years" /><sentence text=" In total, 430,455 warfarin users contributed 407,370 person-years of warfarin use" /><sentence text=" The incidence rate of hospitalization for GI bleeding among warfarin users was 4" /><sentence text="48 per 100 person-years (95% CI, 4" /><sentence text="42-4" /><sentence text="55)" /><sentence text=" Each gastrointestinal bleeding cases was matched to 50 controls based on index date and state" /><sentence text=" Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = 1"><entity charOffset="1-9" id="DDI-PubMed.21731754.s13.e0" text="Warfarin" /><entity charOffset="92-102" id="DDI-PubMed.21731754.s13.e1" text="citalopram" /><pair ddi="false" e1="DDI-PubMed.21731754.s13.e0" e2="DDI-PubMed.21731754.s13.e0" /><pair ddi="false" e1="DDI-PubMed.21731754.s13.e0" e2="DDI-PubMed.21731754.s13.e1" /></sentence><sentence text="73 [95% CI, 1" /><sentence text="25-2" /><sentence text="38]), fluoxetine (OR = 1" /><sentence text="63 [95% CI, 1" /><sentence text="11-2" /><sentence text="38]), paroxetine (OR = 1"><entity charOffset="6-16" id="DDI-PubMed.21731754.s19.e0" text="paroxetine" /></sentence><sentence text="64 [95% CI, 1" /><sentence text="27-2" /><sentence text="12]), amitriptyline (OR = 1"><entity charOffset="6-19" id="DDI-PubMed.21731754.s22.e0" text="amitriptyline" /></sentence><sentence text="47 [95% CI, 1" /><sentence text="02-2" /><sentence text="11])" /><sentence text=" Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR = 1"><entity charOffset="6-17" id="DDI-PubMed.21731754.s26.e0" text="mirtazapine" /></sentence><sentence text="75 [95% CI, 1" /><sentence text="30-2" /><sentence text="35])" /><sentence text="" /><sentence text="Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding"><entity charOffset="29-39" id="DDI-PubMed.21731754.s31.e0" text="citalopram" /><entity charOffset="41-51" id="DDI-PubMed.21731754.s31.e1" text="fluoxetine" /><entity charOffset="53-63" id="DDI-PubMed.21731754.s31.e2" text="paroxetine" /><entity charOffset="65-78" id="DDI-PubMed.21731754.s31.e3" text="amitriptyline" /><entity charOffset="83-94" id="DDI-PubMed.21731754.s31.e4" text="mirtazapine" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e0" e2="DDI-PubMed.21731754.s31.e0" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e0" e2="DDI-PubMed.21731754.s31.e1" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e0" e2="DDI-PubMed.21731754.s31.e2" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e0" e2="DDI-PubMed.21731754.s31.e3" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e0" e2="DDI-PubMed.21731754.s31.e4" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e1" e2="DDI-PubMed.21731754.s31.e1" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e1" e2="DDI-PubMed.21731754.s31.e2" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e1" e2="DDI-PubMed.21731754.s31.e3" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e1" e2="DDI-PubMed.21731754.s31.e4" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e2" e2="DDI-PubMed.21731754.s31.e2" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e2" e2="DDI-PubMed.21731754.s31.e3" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e2" e2="DDI-PubMed.21731754.s31.e4" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e3" e2="DDI-PubMed.21731754.s31.e3" /><pair ddi="false" e1="DDI-PubMed.21731754.s31.e3" e2="DDI-PubMed.21731754.s31.e4" /></sentence><sentence text=" However, the elevated risk with mirtazapine suggests that a drug-drug interaction may not have been responsible for all of the observed increased risk"><entity charOffset="33-44" id="DDI-PubMed.21731754.s32.e0" text="mirtazapine" /></sentence><sentence text="" /></document>